Schrödinger Lifts 2026 ACV and Drug Discovery Guidance as Q3 Revenue Grows 19%
SDGR has more than doubled off its 52-week low of $10.945.
Summary
Schrödinger posted Q3 revenue of $64.5M (+19%) and raised full-year ACV and drug discovery revenue guidance, while correcting an ASH abstract that overstated SGR-1505 development activity.
Key Events · Earnings and Guidance · SDGR
-
Q3 Revenue Up 19% to $64.5M
Total revenue rose to $64.5M from $54.3M, with drug discovery revenue nearly doubling to $24.2M from $13.0M on a Structure Therapeutics milestone payment.
-
Full-Year Guidance Raised
2026 ACV guidance lifted to $222M-$232M (12-17% growth) from $218M-$228M, and drug discovery revenue to $75M-$85M from $65M-$75M.
-
Net Loss Widens on Non-Cash Item
Net loss was $37.7M versus $32.8M, driven by a $14.8M non-cash change in fair value of equity investments; operating expenses fell 13% to $64.4M.
-
ASH Abstract Corrected on SGR-1505
The company said it has not initiated a combination study of SGR-1505 under its FDA-cleared protocol and is exploring strategic opportunities for the program; updated Phase 1 data will be presented at ASH December 12-15, 2026.
Analysis · SDGR · Life Sciences
Schrödinger beat on the top line and lifted both full-year targets: ACV is now guided to $222M-$232M (12-17% growth) versus the prior $218M-$228M, and drug discovery revenue to $75M-$85M from $65M-$75M. Q3 revenue of $64.5M rose 19%, with drug discovery nearly doubling to $24.2M on a Structure Therapeutics milestone. The offset: the quarter's net loss widened to $37.7M from $32.8M, largely a $14.8M non-cash mark-to-market swing on equity investments rather than an operating cash drain. Quietly, the filing also corrects the ASH abstract—there is no ongoing SGR-1505 combination study, and the company is instead seeking partners for that program, a reminder that the proprietary pipeline is being monetized rather than advanced in-house.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SDGR was trading at $30.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $10.95 to $33.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.